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Abstract
Background: The clinical course of idiopathic pulmonary fibrosis (IPF) varies widely. Although the GAP model is
useful for predicting mortality, survivals have not yet been validated for each GAP score. We aimed to elucidate
how prognosis is related to GAP score and GAP stage in IPF patients.
Methods: The Korean Interstitial Lung Disease Study Group conducted a national survey to evaluate various characteristics
in IPF patients from 2003 to 2007. Patients were diagnosed according to the 2002 criteria of the ATS/ERS. We enrolled
1,685 patients with IPF; 1,262 had undergone DLCO measurement. Patients were stratified based on GAP score (0–7): GAP
score Group 0 (n= 26), Group 1 (n= 150), Group 2 (n= 208), Group 3 (n= 376), Group 4 (n= 317), Group 5 (n= 138), Group
6 (n= 39), and Group 7 (n= 8).
Results: Higher GAP score and GAP stage were associated with a poorer prognosis (p< 0.001, respectively). Survival time in
Group 3 was lower than those in Groups 1 and 2 (p= 0.043 and p= 0.039, respectively), and higher than those in groups 4,
5, and 6 (p= 0.043, p= 0.032, and p= 0.003, respectively). Gender, age, and DLCO (%) differed significantly between Groups
2 and 3. All four variables in the GAP model differed significantly between Groups 3 and 4.
Conclusion: The GAP system showed significant predictive ability for mortality in IPF patients. However, prognosis in IPF
patients with a GAP score of 3 were significantly different from those in the other stage I groups and stage II groups of
Asian patients.
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Background
Idiopathic pulmonary fibrosis (IPF) is a specific form of
diffuse interstitial lung disease (DILD) that mainly
occurs in adults over the age of 50 [1]. It is a chronic,
progressive, irreversible, fibrosing interstitial pneumonia,
characterized by limited to the lungs [2]. While the
etiology of IPF is unknown, it is related to a histological
and/or radiological “usual interstitial pneumonia” (UIP)
pattern [1]. Morbidity and mortality are high in IPF—the
median survival time is only 2.5 to 3.5 years—and the clin-
ical course and prognosis vary widely among individual
patients [3]. This high variability makes predicting progno-
sis difficult, which in turn causes problems with treatment
planning. Therefore, physicians must be better equipped to
predict the clinical course of IPF if they are to provide
precise prognoses and adequate treatment to patients.
Previous studies have shown that age, gender, lung
function change, radiological pattern, histological vari-
ability, dyspnoea, cough, pulmonary artery hypertension,
amount of elastic fiber, and some molecular biomarkers
are associated with prognosis [4–10]. Some investigators
have attempted to predict clinical course using these
prognostic factors [11]. However, none of these predictive
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models have been widely adopted, as they are difficult to
use or lack external validation. In 2012, Ley et al. sug-
gested a novel system for staging IPF that is similar to
those used in asthma, chronic obstructive pulmonary dis-
ease (COPD), and lung cancer [12]. The so-called GAP
index and staging system uses of four variables: gender
(G), age (A), and two pulmonary physiological parameters
(P)—percentage predicted forced vital capacity (FVC [%]),
and percentage predicted diffusion capacity of the lungs
for carbon monoxide (DLCO [%]). These four variables are
commonly measured at the initial visit and are easily
followed up. This system has helped clinicians to predict
prognosis and decide on management strategies. Although
this GAP model is simple-to-use for predicting mortality,
prognoses have not yet been evaluated for each GAP
score. The purpose of our study was to validate, using na-
tional survey data, how prognosis is related to GAP score
and GAP stage in patients with IPF.
Methods
Patient selection
The study involved patients who had been diagnosed
with idiopathic interstitial pneumonia (IIP) at 54 university
and teaching hospitals between January 1, 2003 and
December 31, 2007. At each hospital, pulmonary specialists
(pulmonologists, chest radiologists, and pathologists) had
confirmed the diagnoses, and data were reviewed by
the Scientific Committee at the Korean Academy of
Tuberculosis and Respiratory Diseases. IPF was diagnosed
on the basis of the 2002 criteria of the American Thoracic
Society/European Respiratory Society (ATS/ERS) [13].
Initially, we excluded patients who had a history of
connective tissue disease, pneumoconiosis, or inges-
tion of either a cytotoxic agent or amiodarone, and
all of which are well-known to cause interstitial lung
disease. Additionally, we excluded patients with sus-
pected chronic hypersensitivity pneumonitis; such de-
cisions were made on the basis of history, laboratory
data, and committee conference.
In total, 2,186 patients with idiopathic interstitial
pneumonia (IIP) were registered; of these, patients with
other forms of ILD than IPF (n = 501) were excluded
from the study, as were patients who had not undergone
pulmonary function testing (PFT) that included DLCO
measurement (n = 423). Ultimately, 1,262 patients were
included in the study: 760 at GAP stage I, 455 at stage
II, and 47 at stage III (Fig. 1). We reviewed the clinical,
radiological, and physiological data of all the included
patients. With regard to physiological data, we investi-
gated FVC, FVC (%), forced expiratory volume in one
second (FEV1), percentage predicted FEV1 (FEV1 [%]),
total lung capacity (TLC), percentage predicted TLC
(TLC [%]), DLCO, and percentage predicted DLCO (DLCO
[%]). In addition, we evaluated patients’ C-reactive
protein (CRP) levels, and examined their blood for the
positivity of antinuclear antibody (ANA) and rheumatoid
factor (RF). The composite physiologic index (CPI), which
is a predictive model for IPF prognosis, was calculated as
Well et al. reported [14]. All hospital data were entered
into the ILD web-based registry (http://www.ild.or.kr/).
GAP model
Total GAP score was calculated using the method sug-
gested by Ley et al [12] (Table 1). All four clinical vari-
ables were examined: gender (woman: 0 points, man: 1
point), age (0–2 points), FVC (%) (0–2 points), and
DLCO (%) (0–3 points). We then divided the patients on
the basis of GAP score (Groups 0–7): Group 0 (n = 26),
Group 1 (n = 150), Group 2 (n = 208), Group 3 (n = 376),
Group 4 (n = 317), Group 5 (n = 138), Group 6 (n = 39),
and Group 7 (n = 8). In the physiological category, the
“cannot perform” classification (3 points) of DLCO meas-
urement had not been recorded in the data used. For
this reason, the total GAP score of 8 was not investi-
gated in the current study. Additionally, we excluded pa-
tients with total GAP scores of 0 (n = 26), and 7 (n = 8),
as these two groups contained much fewer patients than
Fig. 1 Flow chart showing inclusion and exclusion of patients in the
study. A total of 1262 IPF patients were analysed in this study, excluding
501 with other interstitial lung disease and 423 who had not undergone
pulmonary function testing that had included DLCO. Note: Groups with a
total GAP score of 0 and 7 were excluded because they contained too
few patients and because the baseline characteristics of patients with
GAP score 0 were significantly different (all women, never smokers). No
patients with a GAP score of 8 were included, because the “unable to
perform” category in DLCO was not checked in this study. Definition of
abbreviations: IIP, idiopathic interstitial pneumonia; ILD, interstitial lung
disease; AIP, acute interstitial pneumonia; BOOP, bronchiolitis obliterans
organizing pneumonia; DIP, desquamative interstitial pneumonia; LIP,
lymphocytic interstitial pneumonia; NSIP, non-specific interstitial
pneumonia; RB-ILD, respiratory bronchiolitis-associated interstitial
lung disease
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the other groups. The characteristics in Group 0, which
contained only women who had never smoked, were sig-
nificantly different from those in the other groups.
Statistical analysis
Information was obtained from web-based question-
naires and medical records; it was stored and analysed
using the Excel™ computer program. Analysis of variance
(ANOVA) was used to compare continuous variables,
and Bonferroni’s correction was used for post-hoc ana-
lysis. Pearson’s chi-squared test or Fisher’s exact test
were used to compare categorical variables. Continuous
variables were presented as mean ± standard deviation,
or proportions within each group as a percentage.
To compare the GAP score groups in terms of survival
times, Kaplan-Meier survival analysis and the log-rank
test were used. In addition, multivariate analysis was
conducted with Cox proportional hazard model. C-
statistic was also performed for the GAP model at
1-year, 2-year, and 3-year. When performing the survival
analysis, we censored the following conditions: (1) still
alive at last visit (at last visit date), (2) lost to follow-up
loss and (3) had undergone lung transplantation (at sur-
gery date). Statistics were analysed using SPSS™ Version
20 (SPSS, Chicago, IL, USA). An adjusted p-value less
than 0.05 was regarded as statistically significant.
Results
Demographic characteristics
There were 1,228 patients with a GAP score from 1 to 6.
The baseline characteristics of these patients are summa-
rized in Table 2. The mean age of the study population
was 67.5 ± 9.3 years and was lowest in Group 1. The high-
est proportion of men occurred in Group 6 (p < 0.001).
Although the patients in Group 1 had experienced the
longest duration of respiratory symptoms at diagnosis,
and those in Group 6 had experienced the shortest, this
was not statistically significant (p = 0.133). With regard to
smoking status, 83.3 % of patients in Group 6 were ever-
smokers; the equivalent values in Groups 1 and 2 were
58.7 and 50.5 %, respectively. Furthermore, smoking dur-
ation and amount were higher in Group 6 than in the
other score groups (p < 0.001 and p = 0.024, respectively).
Patients with a higher GAP score tended to have been
diagnosed using the clinical method rather than surgical
lung biopsy. Specifically, the proportion of clinically diag-
nosed patients was 87.2 % in Group 6, whereas it was
22.0 % Group 1. The percentages of ANA and RF positiv-
ity did not differ significantly among the groups (p = 0.580
and p = 0.177, respectively). Increased CRP level was sig-
nificantly associated with higher GAP score (p < 0.001).
CPI also tended to increase as GAP score increased
(p < 0.001). The mean value of CPI was significantly differ-
ent between Group 3 and Group 4, although there was no
significant difference between Group 2 and Group 3 after
Bonferroni’s correction. The mean follow-up duration of
the study population was 19.0 ± 16.0 months.
Physiological and radiological parameters
We investigated pulmonary function, ABGA results, and
HRCT findings in IPF patients (Table 3). In Group 1,
FVC (%) and DLCO (%) were, respectively, 85.6 and
75.8 %, while in Group 6 the values were 55.5 and
31.9 %. ABGA also differed significantly among groups.
Resting pulmonary oxygen tension (PaO2) was highest in
Group 1, and higher GAP score was significantly associ-
ated with lower pulmonary oxygen tension (p < 0.001).
In terms of radiological findings, the groups did not
differ in any parameter other than reticular pattern.
Comorbidities and initial respiratory symptoms
Co-morbidities and initial presenting respiratory symp-
toms are shown in Additional file 1: Tables S1 and S2.
The most common co-morbidities were past history of
tuberculosis, diabetes mellitus, and hypertension; specif-
ically, past history of tuberculosis was in 147 patients
(12.0 %), diabetes mellitus in 234 (19.1 %), and hyperten-
sion in 271 (22.1 %). Furthermore, 74 patients (6.0 %)
Table 1 GAP index and number (%) of patients
Variables GAP Points No. of patients
Gender
Female 0 315 (25.7)
Male 1 913 (74.3)
Age, yr
≤60 0 263 (21.4)
61–65 1 208 (16.9)
>65 2 757 (61.6)
Physiology
FVC, % predicted
>75 0 626 (50.9)
50–75 1 540 (44.0)
<50 2 62 (5.0)
DLCO, % predicted
>55 0 735 (59.9)
36–55 1 399 (32.5)
≤35 2 94 (7.6)
Can not perform 3 -
GAP stage
Stage I 0–3 760 (60.2)
Stage II 4–5 455 (36.1)
Stage III 6–8 47 (3.7)
Note: Values in parentheses are percentages
GAP gender, age, and 2 lung physiology variables (FVC and DLCO)
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had lung cancer. These co-morbidities were not signifi-
cantly different among groups. Fourteen patients (1.1 %)
had a family history of IPF (data not shown). Cough,
sputum, and hemoptysis were significantly more
frequent at higher GAP scores (p = 0.004, p < 0.001, and
p = 0.021, respectively). Although the proportion of pa-
tients who suffered dyspnoea of exertion increased as
GAP score increased, this association was not statisti-
cally significant.
Survival analysis on the basis of GAP score
All GAP variables showed significant association with
prognosis except gender (G) (Table 4, Additional file 1:
Table S3). The C-statistic values for the GAP stage at 1, 2,
and 3 years were 0.59 (CI 0.537–0.638), 0.59 (CI 0.544–
0.631), and 0.57 (CI 0.530–0.611), respectively. The GAP
score showed a similar C statistic value with GAP stage. It
was 0.61 (CI 0.556–0.653), 0.61 (CI 0.566–0.649), and 0.59
(0.549–0.627), respectively. Kaplan-Meier analysis was
performed to compare survival among groups, as well as
among GAP stages (Fig. 2a and b). Advanced GAP stage
was associated with poor prognosis (p < 0.001). At GAP
stages I and II (Groups 1–5), Group 3 differed significantly
from all other groups in terms of cumulative survival
(Group 3 vs. Group 1, p = 0.027; Group 3 vs. Group
2, p = 0.022; Group 3 vs. Group 4, p = 0.025; Group 3
vs. Group 5, p = 0.001). The causes of death are
shown in Table 5. Respiratory failure (42.3 %) and
infection (34.2 %) were the most common causes of
death in study population.
Sub-analysis by GAP score
Table 6 shows the distribution of GAP points in each
group in terms of predictive variables. Higher GAP
scores were significantly associated with male predomin-
ance, aging, and poorer lung function, same as the ori-
ginal definition of the GAP model. Furthermore, gender,
age, and DLCO (%) differed significantly between Groups
2 and 3, and all four variables in the GAP model differed
significantly between Groups 3 and 4.
Table 2 Baseline characteristics of study population according to total GAP score
Variable Total GAP score (n = 1,228) p-value
1 (n = 150) 2 (n = 208) 3 (n = 376) 4 (n = 317) 5 (n = 138) 6 (n = 39)
Age, yr 56.2 ± 5.7 62.5 ± 8.9 69.0 ± 7.8 71.7 ± 7.6 72.4 ± 7.5 71.8 ± 5.9 <0.001a
Sex, male (%) 91 (60.7) 114 (54.8) 281 (74.7) 269 (84.9) 123 (89.1) 35 (89.7) <0.001
Duration of symptoms at
diagnosis (Month)
15.9 ± 27.9 9.8 ± 15.0 10.7 ± 20.6 10.8 ± 21.8 9.5 ± 17.8 5.4 ± 12.8 0.133
Smoking <0.001
Non-smoker 57 (41.3) 98 (49.5) 106 (31.7) 80 (28.3) 33 (27.3) 6 (16.7)
Former 36 (26.1) 49 (24.7) 139 (41.6) 126 (44.5) 59 (48.8) 19 (52.8)
Current 45 (32.6) 51 (25.8) 89 (26.6) 77 (27.2) 29 (24.0) 11 (30.6)
Smoking duration (yrs) 29.1 ± 9.1 29.8 ± 11.0 37.6 ± 11.6 38.0 ± 13.0 37.4 ± 15.7 41.3 ± 9.0 <0.001a
Smoking amounts (PYrs) 32.1 ± 18.2 30.7 ± 19.5 37.0 ± 18.0 36.6 ± 20.1 38.6 ± 25.7 40.0 ± 17.9 0.024a
Diagnostic method (%) <0.001
Clinical 33 (22.0) 86 (41.3) 235 (62.5) 244 (77.0) 119 (86.2) 34 (87.2)
Surgical 117 (78.0) 122 (58.7) 141 (37.5) 73 (23.0) 19 (13.8) 5 (12.8)
Outcome <0.001
Alive 92 (61.3) 118 (56.7) 167 (44.4) 114 (36.0) 36 (26.1) 10 (25.6)
Dead 24 (16.0) 31 (14.9) 82 (21.8) 83 (26.2) 35 (25.4) 15 (38.5)
Loss 34 (22.7) 59 (28.4) 127 (33.8) 120 (37.9) 67 (48.6) 14 (35.9)
ANA positivity 34 (33.7) 31 (28.4) 63 (37.3) 38 (29.9) 20 (35.1) 4 (23.5) 0.580
RF positivity 21 (20.4) 18 (16.5) 42 (24.1) 36 (28.3) 14 (29.2) 2 (11.1) 0.177
CRP (mg/L) 1.3 ± 3.4 2.2 ± 4.3 4.0 ± 11.5 5.9 ± 15.9 7.6 ± 22.1 14.2 ± 38.7 <0.001a
CPI 28.0 ± 10.8 34.9 ± 12.3 35.8 ± 14.9 42.8 ± 12.8 55.7 ± 8.0 62.9 ± 6.8 <0.001a
Note: Values in parentheses are percentages.
CPI = 91.0 – (0.65 apercent predicted DLCO) – (0.53
apercent predicted FVC) + (0.34 apercentage predicted FEV1)
GAP gender, age, and 2 lung physiology variables (FVC and DLCO), ANA antinuclear antibody, RF rheumatoid factor, CPI composite physiologic score
athe following post hoc comparisons were significant at the p = 0.05 level; all other comparisons were non-significant: Score 1 group versus Score 2, 3, 4, 5, 6
groups, Score 2 group versus Score 3, 4, 5, 6 groups, and Score 3 group versus Score 4, 5 groups (age); Score 1 group versus Score 3, 4, 5, 6 groups and Score 2
group versus Score 3, 4, 5, 6 groups (smoking duration); Score 1 group versus Score 6 group, Score 2 group versus Score 6 group, and Score 3 group versus Score
6 group (CRP); Score 1 group versus Score 2, 3, 4, 5, 6 groups, Score 2 group versus Score 4, 5, 6 groups, Score 3 group versus Score 4, 5, 6 groups, Score 4 group
versus Score 5, 6 groups and Score 5 group versus Score 6 group (CPI)
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Discussion
The GAP model is simple to use in planning treatment
or providing prognosis information to IPF patients.
However, prognosis in relation to individual score
groups have not been studied until now. This study
attempted to undertake external validation of the GAP
model in a relatively large cohort of IPF patients. Herein,
we found that GAP score groups differed in terms of
survival: in particular, survival in Group 3 patients dif-
fered from the other stage I groups, as well as the stage
II groups.
For a long time, clinicians who care for IPF patients
have been struggling to make accurate prognoses,
because IPF is a heterogeneous disease that lacks a vali-
dated predictive model [11, 15]. Many previous re-
searchers have aimed to find an ideal model for
predicting clinical outcome in IPF patients [14, 16–22].
In 2001, for instance, King et al. [16] created an
upgraded version of a previously existing clinical, radio-
logical, and physiological scoring system, known as the
“CRP system”, [17] to predict survival in IPF patients.
This model took into account age, smoking status, club-
bing of the fingertips, HRCT score, HRCT score for pul-
monary hypertension score, TLC (%), and PaO2 at max
exercise. However, it did not make clear that gender was
significantly associated with mortality. Furthermore, it
was too complex to use in a clinical setting, and cardio-
pulmonary exercise testing was essential to calculating
the score. Wells et al. [14] then proposed the composite
physiological index (CPI), which used a combination of
three factors to make a prediction—FVC (%), FEV1 (%),
and DLCO (%); these factors are determined using pul-
monary function testing (PFT). Physicians could calculate
CPI using PFT results only, rendering CT findings un-
necessary in predicting prognosis. Besides these models,
du Bois et al. [21] developed a predictive system that was
based on IPF diagnostic criteria, and Richards et al. [22]
used biomarkers to create another predictive model. How-
ever, these models have also been criticized because they
are complicated to use or lack external validation.
Ley et al. developed the GAP model in 2012. Its
straightforward nature has allowed the GAP index to be
widely studied, [23–28] and it has been validated in the
United States, Italy, and South Korea [12, 23]. In fact,
the system showed robust predictive power in patients
Table 4 Survival analysis with Cox proportional hazard model
Variable Univariate Multivariate
HR 95 % CI p-value HR 95 % CI p-value
Age 1.015 1.002–1.028 0.028 1.018 1.005–1.031 0.006
Sex (M/F) 1.184 0.890–1.575 0.245 1.264 0.949–1.684 0.109
FVC (%) 0.985 0.978–0.992 <0.001 0.986 0.979–0.993 <0.001
DLCO (%) 0.987 0.981–0.993 <0.001 0.989 0.983–0.995 0.001
FVC forced vital capacity, % pred percentage of the predicted value, DLCO,
diffusing capacity of the lung for carbon monoxide
Table 3 Initial physiologic and radiologic characteristics according to total GAP score
Variable Total GAP score (n = 1,228) p-value
1 (n = 150) 2 (n = 208) 3 (n = 376) 4 (n = 317) 5 (n = 138) 6 (n = 39)
Pulmonary function test
FVC (%) 85.6 ± 13.4 81.9 ± 17.4 81.3 ± 17.2 71.4 ± 15.7 63.2 ± 15.1 55.5 ± 12.9 <0.001a
FEV1 (%) 93.1 ± 15.0 91.4 ± 21.2 92.5 ± 19.5 82.9 ± 16.8 74.4 ± 16.2 64.9 ± 14.9 <0.001
a
TLC (%) 90.8 ± 19.7 84.8 ± 19.7 87.2 ± 18.5 80.2 ± 18.6 72.0 ± 15.6 67.1 ± 23.9 <0.001a
DLCO (%) 75.8 ± 15.8 67.4 ± 17.1 67.1 ± 21.3 59.2 ± 19.9 41.7 ± 13.6 31.9 ± 11.1 <0.001
a
Resting PaO2 mm Hg 90.5 ± 21.2 85.8 ± 19.6 82.5 ± 22.3 78.6 ± 18.7 74.5 ± 21.5 69.5 ± 13.7 <0.001
a
Resting PaCO2 mm Hg 39.3 ± 8.2 39.2 ± 6.5 37.4 ± 7.8 36.5 ± 6.2 35.1 ± 6.9 36.7 ± 6.4 <0.001
a
Radiologic finding
Reticular pattern 108 (75.5) 144 (73.5) 214 (60.5) 185 (65.4) 82 (65.6) 22 (62.9) 0.008
Honeycombing change 105 (77.2) 141 (71.9) 282 (78.6) 241 (81.4) 110 (84.0) 31 (81.6) 0.101
Ground glass opacities 98 (68.5) 132 (68.4) 206 (58.9) 155 (58.5) 67 (56.3) 22 (68.8) 0.052
Nodular lesions 26 (20.3) 37 (19.9) 85 (25.5) 58 (23.6) 23 (21.9) 8 (25.8) 0.702
Note: Values in parentheses are percentages
GAP gender, age, and 2 lung physiology variables (FVC and DLCO), FVC forced vital capacity, % pred percentage of the predicted value, FEV1 forced expiratory
volume, TLC total lung capacity, DLCO diffusing capacity of the lung for carbon monoxide, PaO2 arterial oxygen tension, PaCO2 arterial carbon dioxide tension
athe following post hoc comparisons were significant at the p = 0.05 level; all other comparisons were non-significant: Score 1 group versus Score 4, 5, 6 groups,
Score 2 group versus Score 4, 5, 6 groups, Score 3 group versus Score 4, 5, 6 groups and Score 4 group versus Score 5, 6 groups (FVC (%)); Score 1 group versus
Score 4, 5, 6 groups, Score 2 group versus Score 4, 5, 6 groups, Score 3 group versus Score 4, 5, 6 groups and Score 4 group versus Score 5, 6 groups (FEV1 (%));
Score 1 group versus Score 4, 5, 6 groups, Score 2 group versus Score 5, 6 groups, Score 3 group versus Score 4, 5, 6 groups, and Score 4 group versus Score 5, 6
groups (TLC (%)); Score 1 group versus Score 2, 3, 4, 5, 6 groups, Score 2 group versus Score 4, 5, 6 groups, Score 3 group versus Score 4, 5, 6 groups, and Score 4
versus Score 5,6 groups (DLCO (%)); Score 1 group versus Score 3, 4, 5, 6 groups, Score 2 group versus Score 4, 5, 6 groups, and Score 3 group versus Score 5, 6
groups (Resting PaO2); Score 1 group versus Score 4, 5 groups and Score 2 group versus Score 4, 5 groups (Resting PaCO2)
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with chronic ILD (ILD-GAP model) and IPF related to
occupational dust exposure [26, 28]. Furthermore, the
model is more powerful and accurate when follow-up
PFT results are taken into account, [26, 27] and it has
been found that DLCO can be replaced by HRCT fibrosis
score in the GAP model (CT-GAP model) [25].
Interestingly, the duration of respiratory symptoms at
diagnosis was longest in Group 1 and shortest in Group
6, although this was not a significant difference. This
may be due to variations in individual perception of
respiratory symptoms [29]. Hiwatari et al. [30] reported
that IPF patients with mucous hypersecretion had
significantly poor prognosis. In our study, the high score
group showed sputum production significantly more
often than score 1 or 2 group. This could mean that the
patients with a higher GAP score could be more vulner-
able to respiratory infection, which could be a cause of
death. In our study, patients with a score over 3 showed
a higher mortality rate due to infection than score 1 or 2
group. Variables related to smoking were significantly
related to GAP score in this study; the proportion of
ever-smokers, as well as smoking amount, were highest
in Group 6. In other studies however, results have con-
flicted regarding the association between smoking and
prognosis in IPF. Such results are easily influenced by
gender, as well as the “healthy smoker effect” [16, 31]. In
our study, smoking was not significantly associated with
mortality in both univariate and multivariate analyses
(Additional file 1: Table S3). Some investigations have
shown that elevated CRP levels are related to poor prog-
nosis [2, 32]. In the present study, CRP levels were high-
est in Group 6, and GAP score was significantly
associated with CRP level (p < 0.001).
The most common cause of death in IPF patients is
respiratory failure, which results from the progression of
lung fibrosis, rather than comorbidities [3]. Furthermore,
our study revealed no significant differences among the
groups in terms of comorbidities. This suggests that
mortality in IPF can be predicted, because the majority
of mortalities are caused by the IPF itself.
In the present study, prognosis in Group 3 differed
significantly from that in the other score groups, as
Fig. 2 Kaplan-Meier estimates of survival of IPF patients based on (a) GAP stage, and (b) total GAP score. a Advanced GAP stages were significantly
associated with poor prognosis (p < 0.001). b Cumulative survival in GAP score group 3 was significantly different from that in the other GAP score
groups: GAP score 3 vs. GAP score 1, p= 0.043; GAP score 3 vs. GAP score 2, p= 0.039; GAP score 3 vs. GAP score 4, p= 0.043; GAP score 3 vs. GAP score 5,
p= 0.032; GAP score 3 vs. GAP score 6, p= 0.003). Definition of abbreviations: GAP, gender, age, and two pulmonary physiology variables (FVC and DLCO)
Table 5 Causes of death in the study population according to total GAP score
Variable Total GAP score Total
1 (n = 11) 2 (n = 21) 3 (n = 60) 4 (n = 63) 5 (n = 28) 6 (n = 13)
Respiratory failure 8 (72.7) 11 (52.4) 21 (35.0) 25 (39.7) 12 (42.9) 6 (46.2) 83
Infection 2 (18.2) 6 (28.6) 19 (31.7) 26 (41.3) 10 (35.7) 4 (30.8) 67
Heart failure 6 (1.0) 5 (7.9) 2 (7.1) 1 (7.7) 14
Lung cancer 1 (9.1) 4 (19.0) 9 (15.0) 5 (7.9) 2 (7.1) 1 (7.7) 22
Othersa 5 (8.3) 2 (3.2) 2 (7.1) 1 (7.7) 10
Note: Values in parentheses are percentages
The cause of death was investigated in 196 mortality cases
GAP gender, age, and two lung physiology variables (FVC and DLCO)
atrauma or malignancy other than lung cancer
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shown using Kaplan-Meier analysis. This result suggests
that the GAP score of 3 could be divided from the other
stage I scores, thus creating a more refined prognostic
system. Although the GAP model is simple to use and
has proven effective in other chronic ILDs, the staging
system amounts basically to a rough grouping of the
GAP scores (stage I: 0–3 points, stage II: 4–5 points,
and stage III: 6–8 points); the GAP stages I, II, and III
were designed to have lowest 40 % risk, middle 40 %
risk, and highest 20 % risk, respectively. In our study,
Group 3 differed significantly from the other stage I
groups, and from the stage II groups, in terms of all four
predictive variables that contribute to GAP score; the
only exception was FVC (%), which did not differ be-
tween Groups 2 and 3. Although the mean value of lung
function results was similar, age and gender composition
were significantly different between Group 2 and 3. Ley
et al. [12] mentioned that one of the limitations of the
GAP model is its overestimation of risk in lower-risk
groups, and this may be the reason for the lack of sig-
nificant difference in FVC (%) mentioned between
Group 2 and 3. Although the mean value of CPI signifi-
cantly increased as GAP score increased, the difference
of CPI between Groups 2 and 3 was not significant in
our study, unlike GAP score. This might be explained by
a difference in study design between the GAP model and
CPI: GAP uses more clinical data in its model, such as
age and gender, while CPI was created using only PFT
results [12, 14].
Our study did have some limitations. Firstly, patients
were diagnosed using the 2002 ATS/ERS guidelines,
which place more importance on surgical lung biopsy
results than do the 2011 updated guidelines. Also in this
study, the HRCT findings were not quantified as scores,
or classified according to updated guidelines. In addition,
in radiologic findings, traction bronchiectasis was not
investigated. However, Ley et al. [12] created the GAP
model using a derivation cohort and validation cohort that
had been diagnosed between 2000 and 2010. Additionally,
Kim et al. [23] demonstrated that the GAP model was
effective (except in predicting the 3-year risk of death) in
Korean IPF patients who had been diagnosed between
2005 and 2009. Another limitation is that Groups 0 and 7
were excluded from the study because they contained
much fewer patients than the other score groups. In fact,
patients in Group 0 (all women, never smokers) differed
significantly from the other score groups in terms of base-
line characteristics. Furthermore, no patients were
enrolled who had a GAP score of 8, which requires the
inclusion of an “unable to perform” category in DLCO
measurement. We also excluded patients who had not
undergone PFT that included DLCO. This considerable
number of excluded groups may have led to selection bias.
Finally, the Korean ILD group did not investigate the
Table 6 Distribution of GAP points by each predictor according to total GAP score
Variable GAP Points Total GAP score (n = 1,228) p-value
1 (n = 150) 2 (n = 208) 3 (n = 376) 4 (n = 317) 5 (n = 138) 6 (n = 39)
Gender <0.001
Female 0 59 (39.3) 94 (45.2) 95 (25.3) 48 (15.1) 15 (10.9) 4 (10.3)
Male 1 91 (60.3) 114 (54.8) 281 (74.7) 269 (84.9) 123 (89.1) 35 (89.7)
Age, yr <0.001
≤60 0 121 (80.7) 76 (36.5) 45 (12.0) 15 (4.7) 6 (4.3) -
61–65 1 29 (19.3) 76 (36.5) 66 (17.6) 24 (7.6) 12 (8.7) 1 (2.6)
>65 2 - 56 (26.9) 265 (70.5) 278 (87.7) 120 (87.0) 38 (97.4)
Physiology
FVC, % predicted <0.001
>75 0 127 (84.7) 134 (64.4) 249 (66.2) 94 (29.7) 22 (15.9) -
50-75 1 23 (15.3) 71 (34.1) 121 (32.2) 211 (66.6) 92 (66.7) 22 (56.4)
<50 2 - 3 (1.4) 6 (1.6) 12 (3.8) 24 (17.4) 17 (43.6)
DLCO, % predicted <0.001
>55 0 143 (95.3) 172 (82.7) 263 (69.9) 147 (46.4) 10 (7.2) -
36–55 1 7 (4.7) 35 (16.8) 108 (28.7) 156 (49.2) 81 (58.7) 12 (30.8)
≤35 2 - 1 (0.5) 5 (1.3) 14 (4.4) 47 (34.1) 27 (69.2)
Note: Values in parentheses are percentages
“Cannot perform” in DLCO was not recorded in this study
Total GAP score 3 group was compared with each group 2 and group 4 by Bonferroni adjustment. The following post hoc comparisons were significant at the
adjusted p value = 0.05; Score 3 group versus Score 2 group (Gender, age, and DLCO, % predicted); Score 3 group versus Score 4 group (Gender, age, FVC, %
predicted and DLCO, %predicted)
GAP gender, age, and 2 lung physiology variables (FVC and DLCO)
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radiologic scoring of fibrosis, dyspnea scale, and pulmon-
ary artery hypertension, which could have provided more
information on prognosis in IPF patients.
Conclusion
In summary, this study was designed as a national valid-
ation study to evaluate GAP scores in relation to the
prognosis of patients with IPF. On the basis of our study
results, we suggest that Group 3 could be separated
from other GAP stage I patients and that reporting this
score separately would improve mortality prediction.
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Additional file 1: Table S1. Comorbidities of idiopathic pulmonary fibrosis
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